Copb2 is essential for embryogenesis and hypomorphic mutations cause human microcephaly

Abstract

Primary microcephaly is a congenital brain malformation characterized by a head circumference less than three standard deviations below the mean for age and sex and results in moderate to severe mental deficiencies and decreased lifespan. We recently studied two children with primary microcephaly in an otherwise unaffected family. Exome sequencing identified an autosomal recessive mutation leading to an amino acid substitution in a WD40 domain of the highly conserved Coatomer Protein Complex, Subunit Beta 2 (COPB2). To study the role of Copb2 in neural development, we utilized genome-editing technology to generate an allelic series in the mouse. Two independent null alleles revealed that Copb2 is essential for early stages of embryogenesis. Mice homozygous for the patient variant (Copb2^R254C/R254C) appear to have a grossly normal phenotype, likely due to differences in corticogenesis between the two species. Strikingly, mice heterozygous for the patient mutation and a null allele (Copb2^R254C/Zfn) show a severe perinatal phenotype including low neonatal weight, significantly increased apoptosis in the brain, and death within the first week of life. Immunostaining of the Copb2^R254C/Zfnbrain revealed a reduction in layer V (CTIP2⁺) neurons, while the overall cell density of the cortex is unchanged. Moreover, neurospheres derived from animals with Copb2 variants grew less than control. These results identify a general requirement for COPB2 in embryogenesis and a specific role in corticogenesis. We further demonstrate the utility of CRISPR-Cas9 generated mouse models in the study of potential pathogenicity of variants of potential clinical interest.

Introduction

Autosomal recessive primary microcephaly is a rare congenital brain defect resulting in a reduction of occipitofrontal head circumference by at least three standard deviations. Patients with microcephaly are typically afflicted with varying degrees of intellectual disability and can either be part of a syndromic condition or an isolated malformation (1,2). To date, mutations in at least 12 genes have been identified in patients with primary microcephaly. The roles of these genes include proper orientation of the mitotic spindle, the duplication, formation or function of the centrosome, DNA-damage response, transcriptional regulation and vesicle trafficking. Most of these mutated genes ultimately play roles in neural progenitor proliferation during the intricate development and organization of the cerebral cortex (3–11).

While there has been significant progress identifying genetic causes of primary microcephaly, the genetics of neurodevelopmental disorders remains incompletely understood (12). In these cases, exome sequencing has become an efficient tool for the identification of rare disease variants. We performed exome sequencing in a pedigree with two affected siblings with primary microcephaly and identified a homozygous recessive variant in the coding region of Coatomer Protein Complex Subunit Beta 2 (COPB2).

COPB2 encodes β’-COP, a subunit of the Golgi Coatomer complex (COPI), which is necessary for retrograde trafficking from the Golgi to the Endoplasmic Reticulum [ER; (13–16)]. In addition to its structural role in the COPI complex, β’-COP has been shown to directly interact with cargo (17,18) and with regulators of intracellular trafficking. In order to test our hypothesis that the microcephaly and other congenital malformations seen in the affected patients are due to the missense mutation in the coding region of COPB2, we used genome-editing technology to generate an allelic series in the mouse. Our results indicate that complete loss of Copb2 is incompatible with embryonic survival to the organogenesis stage of embryonic development, and that compound heterozygotes for a null allele and the missense allele of Copb2 show both brain and growth defects in mice. Thus, we have identified a novel causal gene for primary microcephaly and a requirement for this gene in early mammalian development.

Results

Homozygous recessive mutation in Copb2 identified in two patients with primary microcephaly

Two affected children presented in our hospital with abnormal head size, severe developmental delay, failure to thrive, cortical blindness and spasticity. Both parents and a sibling were healthy with no features of microcephaly (Fig. 1A). Magnetic resonance imaging confirmed microcephaly with a simplified gyral pattern, thin corpus callosum, slight dilation of the lateral, third and fourth ventricles, enlarged extra-axial space and delayed myelination (Fig. 1B–E). Occipital head circumference was well below the 3^rd percentile at all ages for both affected children (Table 1). The low body weight and proportional reduction in head size became more severe in each child as they aged (Fig. 1F–I). In contrast to these measurements, the height of both children was well within the range of normal growth. To further define the microcephaly phenotype based on clinical classifications (2) and to determine whether the clinical phenotype could differentiate between a role for proliferation and/or atrophy in the underlying mechanism, we performed a detailed analysis of the brain imaging studies. We measured the extra-axial fluid spaces in the area of the cisterna magna and sylvian fissures and sizes for the atrium of the lateral, third and fourth ventricles over development of the affected children. This analysis showed a progressive increase in brain ventricle size and minimal change in extra-axial space dimensions (Table 2) suggesting progressive central brain volume loss.

To determine the genetic origin of this syndrome, an initial series of microcephaly genes (ASPM, CK5RAP2, CENP, MCPH1, STIL) was sequenced in the proband with negative results. The affected siblings had a SNP microarray analysis performed using the Illumina Infinium Assay to assess copy number variation (CNV) and regions of homozygosity (ROH). Subsequent analysis did not identify any pathogenic CNV’s but did find a single large ROH in both the proband and her affected brother, despite parental report of non-consanguinity (Fig. 1J). The 16.8 Mb ROH was identified at 3q22.1q24 and contained approximately 90 Refseq genes.

Whole exome sequencing (Illumina Hi Seq 2000) was performed for the two affected children and their parents after obtaining informed consent according to our Cincinnati Children‘s Hospital Medical Center (CCHMC) IRB-approved protocol. Alignment and variant detection was performed using the Broad Institute’s web-based Genome Analysis Tookit (GATK; Genome Reference Consortium Build 37) (19). Quality control and data filtering were performed on VCF files in Golden Helix‘s SNP and Variation Suite. Non-synonymous coding variants were compared with three control databases, including NHLBI’s ESP6500 exome data (20), the 1000 genomes project (21), and an internal CCHMC control cohort (22). The initial bioinformatics analysis identified 126, 752 variants (Table 3). After filtering for quality control using filters previously described (22), coding variants, non-synonymous variants, and minor allele frequencies, we identified one single mutation which followed a homozygous recessive inheritance pattern. The identified variant was compared with known disease genes in the OMIM and Human Gene Mutation (HGMD) (23) databases, and to reported variants in dbSNP (24) and the Exome Aggregation Consortium [ExAC; (25)]. There is one reported heterozygous variant in this position in the Exac database coding for a different missense variant (p.R253H). The variant was also analyzed using Interactive Biosoftware‘s Alamut v2.2 to determine location of mutation within a protein domain, the conservation of the amino acid, the Grantham score (26) and the designation of the mutation by three existing insilico software tools; including a SIFT classification of ‘damaging’ (27), and a Mutation Taster designation as ‘disease-causing’ (28).

The identified variant is a missense mutation in the gene Coatomer Protein Complex, Subunit Beta 2 (COPB2). Consistent with the microarray data, this mutation was within the previously identified region of homozygosity on 3q22.1q24. We confirmed this exome result by Sanger Sequencing in all participants sequenced and extended the Sanger analysis to the unaffected sibling, who was heterozygous for the COBP2 mutation (Fig. 1K). The missense mutation in exon 8 of COPB2 (c.760 C > T; p.Arg254Cys) occurs at a highly conserved residue in a conserved region of the protein (Fig. 1L). The affected amino acid is within a predicted WD40 protein-binding domain (Fig. 2A). Copb2 is highly expressed in the mouse ventricular zone (VZ) where neuroprogenitor cell division occurs in both mouse and human (29). This expression pattern is consistent with a model wherein reduction or loss of COPB2 function could cause primary microcephaly.

A Copb2 allelic series in mouse

In order to validate our results in a mammalian system and to further explore the role of COPB2 in development, we generated several alleles in the mouse. The first allele, Copb2^em1Rstot(Copb2^Zfn), is a Zinc-Finger nuclease mediated 5 bp deletion within exon 12 which encodes a premature stop codon ten amino acids downstream of the deletion (Fig. 2A–D). PCR amplification of a 79 bp region surrounding the deletion allowed us to distinguish the two species upon gel electrophoresis (Fig. 2E). We then used CRISPR-Cas9 technology to generate a "humanized" allele, Copb2^em2Rstot (Copb2^R254C), with the missense variant seen in the patients (Fig. 2A, F, G, I). In the process of creating the Copb2^R254C allele, animals were also created with a one base pair insertion downstream of desired missense mutation site, creating another premature stop, Copb2^em3Rstot, (Copb2^null; Fig. 2A, F, H, I).

Copb2 is indispensable for embryogenesis

Given the integral role Copb2 plays in cellular trafficking as a subunit of the Golgi Coatomer Complex, we hypothesized that loss of Copb2 would severely impair embryogenesis. Results from both of our presumed null alleles (Copb^Zfn and Copb2^null) supported this hypothesis. Of 35 embryos from E11.5-E18.5, and 11 from E7.5-E10.5 recovered from Copb2^Zfn/wtintercrosses, no homozygous Copb2^Zfn/Zfn embryos were recovered. Similarly, no Copb2^null/null embryos were recovered at E12.5 (Table 4). In many cases, there was evidence of early embryonic resorption, consistent with early lethality.

Copb2^R254C/R254C mice do not display any developmental abnormalities

Mice homozygous for the R254C allele are born in Mendelian ratios (Table 4) and are not physically distinct from littermate controls. Analysis of gross brain morphology and histology using Nissl staining did not reveal any discernable abnormalities in the brains of R254C homozygous or heterozygous animals compared with controls (Fig. 3A–I). Body mass at both P21 and P60 was similar across all genotypes (Fig. 3J). At 2 months of age, brain mass, forebrain area, and cell density appeared similar across all three genotypes (Fig. 4K–M). Immunoblots for COPB2 show no significant decrease in protein levels in Copb2^R254C/wtheterozygous or Copb2^R254C/R254Chomozygous animals (Fig. 4N).

Copb2^R254C/Zfn mice are perinatal lethal with cortical malformations

As Copb2^R254C/R254C mice appeared phenotypically normal, we hypothesized that the mouse brain is less sensitive to reductions in Copb2 function than human. In order to test this hypothesis and further assess pathogenicity of the R254C allele, we generated Copb2^R254C/Zfn animals. These pups were not born in Mendelian ratios (Table 4) and could be easily identified among littermate controls due to their small and sickly appearance, usually lacking a milk spot. Body mass was decreased in both P0 and P1 Copb2^R254C/Zfn mice as compared with controls (Fig. 4A). (With the exception of one litter in which all 4 Copb2^R254C/Zfn survived the perinatal period but were morbid at P19, all Copb2^R254C/Zfnanimals were euthanized by P3 due to the excessive morbidity.) Additionally, both the mass and the cortical area of the Copb2^R254C/Zfn brains were reduced compared with controls (Fig. 4B and C). Western blots revealed a significant reduction in COPB2 protein levels in Copb2^R254C/Zfnmice (approximately 50%; Fig. 4D). Histological analysis of Copb2^R254C/Zfn brains showed morphologically normal but reduced cortical tissues as compared with wild type controls (Fig. 4E–J).

We began a molecular analysis of the Copb2^R254C/Zfn phenotype to determine a potential mechanism for the reduction in cortical size. Immunohistochemistry for post-mitotic neurons using TuJ1 showed a robust population in both Copb2^R254C/Zfn brains and controls (Fig. 5A and B). Layer marker analysis was performed and we saw no reduction in TBR1-positive (layer VI) neurons in the Copb2^R254C/Zfnbrains compared with control (Fig. 5C–E). In contrast, we saw a reduction in the later-born CTIP2-positive neurons (layer V) with a 32% reduction in Copb2^R254C/Zfnperinatal brains (P<0.05, Fig. 5F–H). Immunostaining for apoptosis using Cleaved-Caspase 3 (CC3) antibodies at P0 showed significant increases in CC3-immunoreactivity in cortex of the Copb2^R254C/Zfn animals (2.68 fold-increase relative to wild-type controls; Fig. 5I–K). Increased cell death was also observed in the hippocampus, midbrain, cerebellum, and hindbrain of Copb2^R254C/Zfn animals as compared with wild-type at P0-P3 (data not shown). In vitro experiments had indicated an increase in abortive autophagy following RNAi inhibition of Copb2, but we did not detect any change in the ratio of LC3-I to LC3-II levels in R254C/Zfn brains (Supplementary Material, Fig. S1A).

Finally, we began to interrogate neurogenesis at earlier developmental stages. We performed immunohistochemical analysis at E13.5 and E14.5 in the embryonic forebrain with phosphorylated histone H3 (pHH3) as a marker for proliferating cells. Quantification of pHH3 positive cells in the neurogenic ventricular zone revealed a slight but significant increase in Copb2^R254C/ZnF proliferation as compared with littermate controls (33% increase, P < 0.05, Fig. 5L–N).

Reduction of Copb2 in mouse neurospheres leads to reduced growth

Based on the decreased patient occipital head circumference and reduced brain size in the Copb2^R254C/Zfn mice, we hypothesized that loss or reduction of COPB2 is associated with neural cell proliferation defects. Neurospheres were dissected from Copb2 targeted animals on embryonic days (E) 12.5–13.5 and cultured in DMEM-F12 medium with B27 and growth factors as described previously (30). In comparison to neurospheres from wild-type embryos, we saw reduced cell numbers in all genotypes tested at 3 days in vitro (Supplementary Material, Fig. S2). At 5 days of culture, neurospheres from all Copb2 genotypes still had fewer cells than the wild-type control. However, we noticed that neurospheres from Copb2^R254C/Zfn mice had significantly fewer cells than Copb2^R254C/wtneurospheres, while the Copb2^Zfn/wtneurospheres had an intermediate number of cells. These data are consistent with our conclusions from the in vivo models that decreasing levels of Copb2 are increasingly disrupting neural development.

Discussion

Here, we have identified a novel variant in the coding region of COPB2 in two patients with primary microcephaly, seizures, and failure to thrive. To potentially demonstrate a role for COPB2 in neural development and pathogenicity for this variant, we generated an allelic series in the mouse. We show that Copb2 is required for survival to organogenesis stages. Strikingly, Copb2^R254C/R254C mice appear phenotypically indistinct from littermates and are viable and fertile. However, reducing the proportion of functional Copb2 further by generating Copb2^R254C/Zfn mice leads to perinatal death and cortical malformations. In contrast to previous reports studying depletion of COPI components, the Copb2^R254C/Zfn neural phenotype does not appear to involve an increase in abortive autophagy or ER stress. This study represents the first discovery of a disease-causing variant in COPB2 as well as the first known link between primary microcephaly and a subunit of the COPI complex.

Like most genes linked to microcephaly, COPB2 apparently acts as part of a highly conserved pathway that is essential for life in a wide variety of cellular lineages. This conclusion is supported by our discovery that Copb2^null/nulland Copb2^Zfn/Zfnembryos do not survive to organogenesis (Table 4), and that our attempts to create COPB2-null cell lines were unsuccessful (data not shown). These results are also supported by the literature, where it has been demonstrated that siRNA-mediated reduction of COPB2 in breast cancer cells leads to a drastic reduction in replating efficiency (31). Notably, an early lethality phenotype has also been observed in mice null for other known microcephaly-associated genes, including MCPH7 (STIL), which die in utero after E10.5 (33), and MCPH10 (ZNF335), which die as early as E7.5 (34). Thus, it appears human malformations are more likely due to hypomorphic mutations in these genes where neural development is especially susceptible, likely due to the extremely high rates of neurogenesis in primate cortical development.

The early lethality of Copb2^null/null embryos strongly suggests that the patient mutation is hypomorphic, as an effectively null allele would presumably arrest embryogenesis at a much earlier stage. This assumption proved true in our mouse models: immunoblots of perinatal Copb2^R254C/R254C brains indicate no significant decrease in COPB2 levels, whereas Copb2^R254C/ZnF brains have approximately half the normal amount of protein. The Copb2^R254C mutation is located within the N-terminal WD40 repeat (β-propeller) domain of β’-COP, which has been shown to bind COPI cargo (35). Given the hypomorphic nature of the mutation, one could hypothesize that it interferes with the interaction between β’-COP and this cargo, causing an incremental reduction in COPI trafficking efficiency which is sufficient to cause defects during neurogenesis. Interestingly, the α-COP subunit of COPI shares significant N-terminal homology with β’-COP and has also been shown to bind cargo using its own WD40 repeat domain (36). COPA mutations in this domain result in Copa Syndrome, an immune regulatory syndrome in which the mutated α-COP protein has a reduced ability to bind di-lysine tagged cargo (37). It remains to be seen why COPA mutations result in such a syndrome while COPB2 mutations in the homologous domain result in neurogenesis defects. Presumably, this can be attributed either to the fact that COPB2 binds a unique set of COPI cargo, or to the fact that the COPB2^R254C mutation affects protein function to a different degree than known COPA mutations do. Future experiments to address differentially affected binding partners will be quite interesting in this regard.

Other hypotheses about the underlying mechanism could be based on studies of two other proteins harboring WD40-repeat domains. The first, WDR62, has reported mutations causing microcephaly due to mitotic delay and increased cell death (38). Additionally, another similar protein (WDR45) is associated with neurodegeneration, evidently through autophagy defects (39). However, the unchanged LC3-I/LC3-II levels in Cobp2^R254C/Zfn brain lysates suggest that autophagy is relatively uninterrupted, suggesting this is an unlikely mechanism causing the phenotypes we report here. It is surprising we do not see evidence for deficits in autophagic flux as others have seen upon RNAi mediated depletion of COPB2 in vitro (31,32). We hypothesize that the autophagy defects seen in these knockdown paradigms may represent a more significant decrease in levels of COPB2 than those generated in the genetic models. Indeed, the homozygous null embryos may have autophagy phenotypes, but died so early in development this cannot be tested. The role of Copb2 in regulating autophagy and a possible mechanistic link to microcephaly remains an intriguing possibility for future investigation.

A major difference between the patients discussed here and the mouse models we created was the ability of the mice to tolerate the Copb2^R254C/R254C genotype without an observable phenotype, only exhibiting major defects when overall Copb2 expression was reduced by a Copb2^R254C/Zfn genotype. This issue is not unique to our study, as microcephaly has been historically difficult to model in the mouse, perhaps because mouse corticogenesis only generates around 14 million neurons while the human cortex has around 16 billion (40). Additionally, neurogenesis in gyrencephalic species is much more reliant on basal progenitor proliferation (41), suggesting that phenotypes involving this cell type may not be easily recapitulated in lissencephalic models such as the mouse. In some mouse models of microcephaly, such as MCPH1 (42), and MCPH2 (Wdr62) (38), reductions in cortical size are accompanied by comparable reductions in other brain structures and in overall body size, as was observed in Copb2^R254C/Zfn mice. Additionally, we did find a reduction in layer V CTIP2-positive neurons in the COPB2^R254C/Zfn mice, which is a reported feature in mouse models of microcephaly (43). It is also worth noting that the probands themselves were significantly underweight in addition to being microcephalic (Fig. 1).

In light of the reduction in neurons expressing the cortical layer V marker CTIP2 (Fig. 5F–H) and the significant increase in CNS apoptosis in neonates (Fig. 5I–K), the increased VZ proliferation in E13.5 Copb2^R254C/ZnFbrains is intriguing. Although a complete elucidation of mechanism is beyond the scope of this study, these results invite further investigation. Notably, E13.5 is the peak day for layer V neurogenesis (44). One potential explanation for an increase in VZ proliferation associated with a decrease in layer V is a discrepancy in the ratio of symmetrical to asymmetrical divisions among the progenitor cells (45). This hypothesis could be further tested in the future along with a comprehensive study of the neurodevelopment in these mutants. It also remains to be seen whether this prenatal pHH3 increase is accompanied by an increased apoptotic index before birth as has been seen in multiple models (46).

Although we found differences in cell numbers in the genetically modified neurospheres (Supplementary Material, Fig. S3B), these were not as striking as the in vivo differences between differing mouse genotypes. This could be due to inherent differences in neurospheres in vitro as compared with in vivo neurogenesis. It is notable that all Copb2 allelic combinations show reduced neurosphere growth as compared with wild-type. At 5DIV, the differing genotypes are starting to diverge with the Copb2^R254C/Zfnneurospheres showing a further significant decrease in cell number from Copb2^R254C/wt, a heterozygote for a hypomorphic missense mutation. The reduced growth rate in Copb2^R254C/Zfn neurospheres may decrease even further from the Copb2^Zfn/wt neurospheres (a heterozygote for a null mutation) if the cultures were maintained even further in vitro.

Copb2 variants have not been connected to any human disease prior to this study, although mutations in Copb2 as well as Copa (α-COP) and Copb (β-COP) have been linked to notochord defects in Zebrafish (47). Notably, a protein associated with neurodegeneration, SCYL1, was shown to interact with COPI subunits and to regulate retrograde Golgi to ER traffic (48). Also of note, COPI function (specifically, the δ-COP subunit) was implicated in the trafficking and metabolism of amyloid precursor protein, suggesting a role in Alzheimer‘s progression (49).

Materials and Methods

Subjects

Informed consent was obtained according to Cincinnati Children‘s Hospital Medical Center (CCHMC) institutional review board protocol # 2012–0203. Following consent, whole blood was collected on the parents, residual DNA on the affected individuals, and spit on the unaffected sibling.

Microarray

Affected siblings had microarray analysis performed using the Illumina Infinium Assay (San Diego, CA) with the Illumina HD Human OMNI-quad BeadChip platform. The chip contains approximately 1, 140, 419 probes to assess copy number variation and regions of homozygosity.

Genotyping

Library generation, exome enrichment, sequencing, alignment and variant detection were performed in the CCHMC Genetic Variation and Gene Discovery Core Facility (Cincinnati, OH). Briefly, sheared genomic DNA was enriched with NimbleGen EZ Exome V2 kit (Madison, WI). The exome library was sequenced using Illumina‘s Hi Seq 2000 (San Diego, CA). Alignment and variant detection was performed using the Broad Institute‘s web-based Genome Analysis Tookit (GATK) (19). All analyses were performed using Genome Reference Consortium Build 37.

Variant filtering and pathogenicity assessment

Quality control and data filtering were performed on VCF files in Golden Helix‘s SNP and Variation Suite (Bozeman, MT). Non-synonymous coding variants were compared with three control databases, including NHLBI’s ESP6500 exome data (20), the 1000 genomes project (21), EXAC Browser (25) and an internal CCHMC control cohort (22). Remaining variants were subject to autosomal recessive analysis with emphasis on homozygous recessive variants found in the region of homozygosity identified by SNP microarray. The identified variant was compared with known disease genes in the OMIM and Human Gene Mutation (HGMD) (23) databases, and to reported variants in dbSNP (24) and the Exome Variant Server. The variant was also analyzed using Interactive Biosoftware‘s Alamut v2.2 (San Diego, CA) to determine location of mutation within a protein domain, the conservation of the amino acid, the Grantham score (26) and the designation of the mutation by three existing in silico software tools, SIFT (27), Polyphen (50) and Mutation Taster (28). COPB2 mutations were validated by Sanger Sequencing (see Supplementary Material, Table S1).

Allele generation

Zinc finger nuclease guides were purchased from Sigma (St. Louis, MO) and submitted to the CCHMC Transgenic Core for blastocyst injection. Founder animals were screened with PCR primers (Supplementary Material, Table S1). CRISPR guides targeting the region of interest within exon 8 (ENMUSE00000230688) of mCopb2 were designed using the MIT CRISPR design tool (crispr.mit.edu). Three potential guide RNA (gRNA) sequences were selected and ordered as complementary oligonucleotide pairs with BbsI overhangs (Supplementary Material, Table S1). These were ligated into the pSpCas9(BB)-2 A-Puro (px459) vector and transfected into 3T3 using the Lipofectamine® 3000 transfection reagent (Thermo Fisher Scientific, Massachusetts). 48 h after transfection, the cells were harvested and genomic DNA was purified before being subjected to the Surveyor® mutation detection kit in order to test cutting efficiency (Integrated DNA Technologies, Coralville, IA). As a control, cutting efficiencies of potential mCopb2 guides were compared with that of a previously-published mTet2 gRNA (Integrated DNA Technologies, Iowa). A donor sequence was designed to introduce the desired missense mutation Copb2^R254C modeling the patients’ mutation (Supplementary Material, Table S1). The donor and the plasmid encoding the most efficient mCopb2 gRNA (Guide 3, Supplementary Material, Table S1) were sent to the CCHMC Transgenic Core for blastocyst injections. Potential founders were validated with Sanger Sequencing. pSpCas9(BB)-2 A-Puro (PX459) V2.0 was a gift from Feng Zhang (Addgene plasmid # 62988). All transgenic injections were done into animals from a mixed C57BL/6; DBA/2 background. (C57BL/6 x DBA/2, 2nd generation). Copb2^Zfnmice were maintained on a C57BL/6 J background and all CRISPR/CAS9 alleles were maintained on a CD-1 background.

Animal husbandry

All animals were housed under and approved protocol and standard conditions. All euthanasia and subsequent embryo/organ harvests were preceded by Isoflurane sedation. Euthanasia was accomplished via dislocation of the cervical vertebrae. For embryo collections, noon of the day of vaginal plug detection was designated as E0.5.

Sample measurements (body mass, brain mass). Sacrificed animals were weighed immediately following euthanasia. Control body weights in Figure 4 are a compilation of all unaffected genotypes. Analyses of each discrete genotype did not reveal any significant differences between groups. Brains were removed, weighed, and imaged using a Zeiss SteREO Discovery.V8 stereomicroscope. Relative area was measured using Axiovision 40 software (v.4.8.2.0). Magnification scale was the same for samples of the same age. Box plots were generated with BoxPlotR (http://shiny.chemgrid.org/boxplotr/).

Western immunoblotting. Following euthanasia, P0-P3 brains were dissected, flash-frozen, and weighed. These samples were then homogenized in RIPA buffer and stored at -80 °C. Homogenized samples were diluted in 50: 1 Laemelli Buffer: 2-Mercaptoethanol and heated to 90 °C for 5 min. Samples were then loaded into Novex™ WedgeWell 10–16% Tris-Glycine gels and electroporated at 130 V for 100–130 min in Tris-Buffered Saline. Transfers were performed on ice at 35 V for 90 min in Transfer Buffer (25 mM Tris, 190 mM Glycine, 20% Methanol). The membranes were then washed in TBS and blocking was performed at room temperature in 1: 1 Odyssey® Buffer: PBS. Primary antibody incubation was performed at 4 °C overnight in 1: 1 Odyssey® Buffer: PBS. Membranes were then washed three times in TBS. Membranes were then incubated in IRDye® 680RD and 800CW at room temperature for 1 h and visualized using an Odyssey® CLx Imaging System. Analysis was performed using Image Studio Lite V5.2. Relative band intensity was compared with α-Tubulin loading controls in order to quantify results.

Histological and immunohistochemical analysis. For adult histology and immunohistochemistry (IHC) adult (2 months of age) littermate animals underwent transcardial perfusion using cold heparinized phosphate buffered saline (PBS) and 4% paraformalydehyde (PFA) solution. Brains were dissected and fixed for 72 h in 4% PFA at room temperature followed by immersion in 70% ethanol (for histology). Samples were then paraffin embedded, sectioned at 5um, and processed through hematoxylin and eosin (H&E) staining. Sections were sealed using Cytoseal Mounting Medium (Thermo-Scientific).

For postnatal IHC analysis, P0-P3 pups were euthanized and brains dissected and fixed overnight in 4% paraformaldehyde. Following this, samples were immersed in 30% sucrose solution for 24–48 h until sufficiently dehydrated. Brains were embedded in OCT compound (Tissue-Tek) and sectioned at a thickness of 10uM. For IHC sections were immersed in PBS followed by blocking in 5% normal goal serum in PBST for 1 h and overnight incubation in the following primary antibodies: TuJ1 (1: 500, Sigma), TBR1 (1: 500, Abcam), CTIP2 (1: 200, Abcam), CleavedCaspase3 (1: 300, Cell Signaling), and GFAP (1: 500, Abcam). Sections were washed three times in PBS and incubated at room temperature in AlexaFluor 488 goat anti-rabbit or goat anti-mouse secondary (1: 500, Life Technologies) for 1 h followed by incubation in DAPI (1: 1000) for 15 min. Sections were then rinsed in PBS and sealed with ProLong Gold Antifade Reagent (Life Technologies). For postnatal histology sections were rinsed in PBS followed by processing through H&E and Nissl staining. Sections were sealed using Cytoseal Mounting Medium (Thermo-Scientific). Embryos were harvested and cryoembedded using standard procedure. IHC for pHH3 (1: 500, SIGMA) was as detailed above. All IHC sections were imaged on Nikon C2 Confocal microscope. All paired images were taken at the same magnification.

Quantification of cortical cell number. Images were imported into Image J (Schneider et al., 2012) and areas were established around the region of interest in the cortex. Thresholding was used to detect specific populations in each channel (DAPI and GFP) and quantified using the Analyze Particles function. All cell measurements are normalized to the areas recorded in each respective sample.

Supplementary Material

Supplementary Material is available at HMG online.

Funding

Cincinnati Children‘s Research Foundation and National Institutes of Health (R01NS085023 to R.W.S.)

Conflict of Interest statement. None declared.

References

Author notes